AFP and cancer: Regarding proteomic biomarkers, the clinical applications of cancer-associated antigens such as CEA, AFP, CA199, and CA125 have been extensively researched (Leja and Linē, 2021), yet their effectiveness remains constrained owing to low sensitivity and accuracy, typically around 30%.